ConcertAI and Foundation Medicine to link real-world clinical data with genomics to advance oncology research

A new collaboration between ConcertAI and Foundation Medicine brings together large-scale genomic testing data and longitudinal clinical records to create a clinically linked oncology dataset for life sciences research. Through the integration of de-identified multimodal genomic data with high-quality clinical information, the companies aim to provide a more complete view of the cancer patient journey and more robust evidence to inform development decisions across oncology. 

The integrated dataset is intended to support translational research, real-world evidence (RWE) generation, and more efficient drug development. With the addition of Foundation Medicine’s data, ConcertAI is now able to offer what the company describes as the “largest and most comprehensive clinically-linked dataset” available to industry, representing nearly half a million patients across its partner network. The resource is designed for use across the drug development lifecycle, from early discovery and translational research through clinical development and post-approval evidence generation. 

The collaboration comes as oncology development programs face growing complexity, longer timelines, and tighter budgets. As trials become more targeted and resource-intensive, access to well-linked genomic and clinical data is increasingly important for shaping early research hypotheses, refining trial design, and reducing uncertainty around patient selection and outcomes. 

By linking Foundation Medicine’s genomic testing portfolio with ConcertAI’s longitudinal clinical datasets, the combined resource captures patient information from pre-diagnosis through treatment and outcomes. The companies say this end-to-end perspective is intended to reduce reliance on assumptions in early research, improve study planning, and support faster therapy development while maintaining methodological rigor. Eron Kelly, CEO of ConcertAI, stated: 

“Drug developers are increasingly pushed to accelerate their research pipelines but require more robust insights into both early genomic signals and patient outcomes to make this a reality. By combining the largest and deepest set of clinical data with genomic insights, including whole slide imaging, we can help teams set a clearer plan and speed up their projects.” 

Foundation Medicine contributes a broad genomic dataset derived from its clinical testing portfolio, including US Food and Drug Administration (FDA)-approved companion diagnostic indications across all four major classes of genomic alterations, as well as multiple genomic signatures. Coverage of these alteration classes enables a more complete view of tumor biology, including changes that can be difficult to detect with some next-generation sequencing approaches, such as MTAP loss. 

Beyond genomic alterations, the integrated resource also includes gene expression data, immunohistochemistry results, and whole-slide images. These molecular and imaging data are linked to one of ConcertAI’s most diverse clinical datasets, capturing variation across socioeconomic status, ethnicity, and rural versus urban populations. Together, these elements are intended to support analyses that better reflect cancer behavior and treatment performance in routine clinical practice over time. 

From a translational research perspective, access to multimodal, clinically linked data is expected to enable more detailed cohort characterization, improved understanding of disease heterogeneity, and earlier identification of signals relevant to treatment response or resistance. In later stages of development, the dataset may support more precise cohort identification, trial feasibility assessments, and RWE studies to complement clinical trial findings. 

Dan Malarek, CEO of Foundation Medicine, highlighted the role of analytics and AI in enabling partners to make use of the integrated resource: 

"By integrating our high-quality genomic data with ConcertAl's electronic health data, we have created one of the most powerful new real-world data sets that enables insights to be turned into strategic decisions at critical milestones for our partners."